orange and white medication pill

Pfizer to Spend $11.6B on Migraine Drug Maker

Migraine headaches are a type of headache that can cause severe pain, nausea, and sensitivity to light and sound. For many people, migraines can be debilitating, making it difficult to work or even go about their everyday lives. There is no cure for migraines, but there are treatments that can help lessen the symptoms.

Pfizer, one of the world’s largest pharmaceutical companies, has announced that it will be spending $11.6 billion to buy Migraine treatment maker biohaven. Biohaven is a company that specializes in Migraine treatments and supplements.

This is a big move for Pfizer, as migraine headaches are a growing problem worldwide. According to the World Health Organization, migraines are the 6th most disabling illness in the world.

What the Acquisition Means for Both Companies

The acquisition will mean that Pfizer will gain access to Migraine treatments that are in development, as well as the knowledge and expertise of the company’s employees. For Biohaven, the deal will give them the resources they need to continue developing Migraine treatments and bring them to market.

Pfizer is not the only company interested in Migraine treatments. Last year, Novartis agreed to pay $85 million for Migraine treatment maker Alder BioPharmaceuticals. And in 2016, Allergan, the maker of Botox, acquired Migraine treatment company Tobira Therapeutics for $1.7 billion.

With Migraines affecting so many people worldwide, it’s no surprise that pharmaceutical companies are interested in developing treatments for this condition. And with Pfizer’s deep pockets, the company is in a good position to continue researching and developing Migraine treatments.

How This Deal Will Affect Drug Prices and Access to Treatment for Migraine Patients Around the World

The deal between Pfizer and Biohaven is still subject to regulatory approval, but if it goes through, it could have implications for Migraine patients around the world.

If Pfizer is successful in developing Migraine treatments, it could mean that Migraine sufferers will have more options when it comes to treatments. And if Pfizer is able to bring Migraine treatments to market quickly, it could also mean that Migraine sufferers will have access to treatments sooner.

However, it’s important to remember that Pfizer is a for-profit company, and the prices of Migraine treatments will likely reflect that. So while this deal could mean more options and quicker access to Migraine treatments, it’s also likely that the treatments will be more expensive.

Only time will tell how this deal will affect Migraine sufferers around the world, but it’s certainly a step in the right direction for those who suffer from this debilitating condition.

In conclusion, the acquisition of Biohaven by Pfizer could mean good things for Migraine sufferers around the world. However, it’s important to remember that Migraine treatments are likely to be more expensive if they are developed by Pfizer. Migraine headaches support is a growing problem worldwide and we hope that with this acquisition, Migraine sufferers will have more options when it comes to treatments.

$29 Billion in Total Sales Expected for Pfizer Vaccine

Although COVID vaccinations have fallen short of goals, Pfizer announced in late 2021 that they expect COVID-19 vaccine sales to reach $65 billion or more through the end of the 2022 fiscal year. That figure represents an expected $29 billion in 2022, which is higher than what analysts expected from the efforts.

The American-based drugmaker created its COVID shot with the help of German partner BioNTech SE.

Pfizer says it’s looking to keep making deals for the vaccine with other countries, which could drive sales much higher than expected. The company announced that it expects to make up to four billion doses.

The sales figures are based on the revenues for 1.7 billion doses being sold. 

How Are the Other Vaccines Faring in Sales?

Moderna reached the market after Pfizer with its COVID vaccine. Although sales have been strong for it, the drugmaker struggled to ramp up production as much as its competitor. Sales in 2021 were revised to be as low as $15 billion, which is about half of what Pfizer was able to achieve.

During the first nine months of 2021, Johnson and Johnson earned just $766 million in revenues from its vaccine. The company announced that it expects several contracts to be fulfilled during the fiscal year’s fourth quarter, which should boost total sales to about $2.5 billion.

AstraZeneca is started to profit from its sales of the COVID vaccine they developed for distribution. The company earned about three times as much as J&J in 2021, with total sales expected to reach $9.74 billion across all its product lines. Vaccine sales reached nearly $2.2 billion. 

If you haven’t gotten your shot yet, experts recommend that you should as more variants emerge. You can also potentially boost immune system strength with Host Defense.